CagriSema for High Blood Pressure in People With Obesity
Tests CagriSema in adults with high blood pressure and obesity.
Plain-language title generated from the registry record
Registry title: A Research Study to Investigate How Well the Medicine CagriSema Lowers High Blood Pressure in People Living With High Blood Pressure and Obesity
Key facts
- Where
- Buenos Aires, CABA, Capital Federal, Godoy Cruz, Mendoza, Rosario, Santa Rosa, and Santiago del Estero, ArgentinaSee the 10 sites
- Phase
- Phase 3
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with high blood pressure and obesity. They will get CagriSema, semaglutide, cagrilintide or placebo, assigned by chance.
- Age
- 18 years or older
- Sex
- Women and men (sex at birth)
- Disease stage
- Resting systolic blood pressure of 140-160 mmHg at screening and at the run-in visit, and body mass index of 30.0 kg/m^2 or more. People with type 2 diabetes can join if diagnosed 90 days or more before screening and HbA1c is 6.5-10.0% (48–86 mmol/mol).
- Earlier treatment
- People must take no blood pressure medicine or SGLT2 inhibitor, or be on a stable dose for 30 days or more before screening. They cannot have used weight-loss medicine, GLP-1 receptor agonists or amylin agonists within 90 days before screening.
- Biomarker or test result
- HbA1c 6.5-10.0% (48–86 mmol/mol) for people with type 2 diabetes. Without type 2 diabetes, HbA1c must be below 6.5% (48 mmol/mol).
Main reasons for not taking part
- Low blood pressure when standing up (orthostatic hypotension)
- High blood pressure caused by another medical condition (secondary hypertension)
- Hospital stay for high blood pressure within 90 days before screening
- Atrial fibrillation at the run-in visit or a history of frequent or long-lasting atrial fibrillation
- Body weight change of more than 5% within 90 days before screening
Read by machine on 9 November 2026.
Where in Argentina
- Centro Medico Dra. Laura Maffei e Investigacion Clínica ApliBuenos Aires, ArgentinaContact: Novo NordiskNo longer taking part
- Cedic - Centro de Investigacion ClinicaCABA, ArgentinaContact: Novo NordiskNo longer taking part
- CEMEDICCABA, ArgentinaContact: Novo NordiskNo longer taking part
- Centro Médico Viamonte SRLCABA, ArgentinaContact: Novo NordiskNo longer taking part
- Mautalen- Salud e InvestigacionCABA, ArgentinaContact: Novo NordiskNo longer taking part
- Centro de Investigaciones MetabólicasCapital Federal, ArgentinaContact: Novo NordiskNo longer taking part
- Hospital Español de MendozaGodoy Cruz, Mendoza, ArgentinaContact: Novo NordiskNo longer taking part
- CAICIRosario, ArgentinaContact: Novo NordiskNo longer taking part
- Fundación CESIMSanta Rosa, ArgentinaContact: Novo NordiskNo longer taking part
- Sanatorio NorteSantiago del Estero, ArgentinaContact: Novo NordiskNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Novo Nordisk A/S
- Trial code
- NCT07919405
- Record updated
- 5 November 2026
- Original description
This study is testing whether CagriSema is safe and works well in adults with high blood pressure and excess body weight. Participants will receive CagriSema, semaglutide, cagrilintide, or placebo, and treatment will be assigned by chance. CagriSema and cagrilintide are investigational medicines, while semaglutide is already available by prescription.Read full original descriptionShow less
Efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema) in Participants With Hypertension and Obesity
This study is testing whether CagriSema is safe and works well in adults with high blood pressure and excess body weight. Participants will receive CagriSema, semaglutide, cagrilintide, or placebo, and treatment will be assigned by chance. CagriSema and cagrilintide are investigational medicines, while semaglutide is already available by prescription.
Inclusion: Male or female (sex at birth); Age 18 years or above at the time of signing the informed consent; Resting in-office SBP of 140-160 mmHg (both inclusive) at screening (V1-Optional/V1) and the Run-in visit. Systolic blood pressure will be calculated as the mean of the second and third consecutive readings of triplicated blood pressure readings collected at 2-minute intervals with the blood pressure monitor provided by the Sponsor; Body mass index greater than or equal to (>=) 30.0 kilograms per metre square (kg/m\^2) at screening; Not receiving Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2i) or antihypertensive medication or on stable (i.e., same drug(s), dose and dosing frequency) SGLT2i or antihypertensive treatment >= 30 days prior to screening; For participants with Type 2 Diabetes (T2D); The following inclusion criteria apply at screening in addition to the inclusion criteria listed above:; Diagnosed with T2D >= 90 days before screening; Glycated Haemoglobin (HbA1c) 6.5-10.0% (48-86 millimoles per mole (mmol/mol)) (both inclusive) as measured by the central laboratory at screening; Treatment with either lifestyle intervention only, or treatment with 1-3 marketed oral antidiabetic drugs (metformin, α-glucosidase inhibitors, glinides, SGLT2i or thiazolidinediones, as a single agent or in combination) according to local label; Treatment with antidiabetic medication should be stable (i.e., same drug(s), dose and dosing frequency) for at least 90 days before screening.
Exclusion: Hospitalisation within the last 90 days before screening for hypertension or hypertensive crisis; A change in body weight greater than (>) 5% within 90 days before screening irrespective of medical records; Treatment with any medication prescribed for the indication of obesity or weight management within 90 days before screening; Use of any Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA), including medication with GLP-1 RA activity, or amylin agonists, within 90 days before screening; For participants without T2D; Known secondary hypertension due to renovascular hypertension (renal artery stenosis), primary aldosteronism, Cushing's syndrome, pheochromocytoma, acromegaly, coarctation of the aorta, or any other identifiable cause of secondary hypertension; Currently under medical investigation for any cause of secondary hypertension; Atrial fibrillation at the Run-in visit or history of frequent intermittent or chronic atrial fibrillation; History of type 1 or type 2 diabetes mellitus; Moderate-to-severe anaemia with Hgb lesser than (<) 10.9 grams per decilitre (g/dL) as measured by the central lab at screening; HbA1c greater than or equal to >= 6.5 % (48 mmol/mol) as measured by the central laboratory at screening; Known orthostatic hypotension or orthostatic hypotension at screening (V1-Optional/V1).